We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » IDM Pharma Receives Not-Approvable Letter for Bone Drug
IDM Pharma Receives Not-Approvable Letter for Bone Drug
August 31, 2007
The FDA issued a not-approvable letter for IDM Pharma’s experimental osteosarcoma drug because the efficacy data was insufficient, the company announced.